In addition to the seven new 2022 ICD-10 procedure codes announced in November, the Centers for Medicare & Medicaid Services on April 1 will implement two new ICD-10 procedure codes for reporting COVID-19 therapeutics. The new codes are for describing the infusion of tixagevimab and cilgavimab monoclonal antibody (code XW023X7), and the infusion of other new technology monoclonal antibody (code XW023Y7).

The Food and Drug Administration last month authorized using the combination monoclonal antibody therapy Evusheld (tixagevimab co-packaged with cilgavimab) to help prevent COVID-19 in certain adults and children with compromised immune systems or a history of severe adverse reaction to a COVID-19 vaccine or its components.
 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services today released updated interpretive guidance on its Omnibus COVID-19 Health Care Staff Vaccination…
Blog
To help hospitals and health system leaders stay up-to-date on all of the legal developments related to vaccine mandates, the AHA has developed a blog…
Headline
Leaders from the AHA and the American College of Obstetricians and Gynecologists, hospital leaders, clinicians and experts from the Centers for Disease Control…
Headline
A new AHA video is tackling prominent myths about COVID-19 and its vaccines, providing the public with the facts they need to make sound health decisions…
Headline
The Food and Drug Administration has revised its provider and recipient fact sheets for the Johnson & Johnson COVID-19 vaccine due to reports of…
Headline
The Centers for Medicare & Medicaid Services has approved a new Healthcare Common Procedure Coding System code J0248 for the VEKLURY (remdesivir) antiviral…